Related Experiment Video

Updated: May 9, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression

Sebastien Taurin1, Kirstie M Allen, Marissa J Scandlyn

  • 1Department of Pharmacology and Toxicology, University of Otago, Adams Building, Dunedin 9016, New Zealand.

International Journal of Oncology
|July 12, 2013
PubMed

Insights

Raloxifene effectively inhibits triple-negative breast cancer (TNBC) growth and promotes regression in mouse models. This therapy targets epidermal growth factor receptor (EGFR) independently of estrogen receptors, offering a potential new treatment for TNBC.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) presents a poor prognosis with limited targeted therapies.
  • Selective estrogen receptor modulators (SERMs) like raloxifene may offer therapeutic benefits independent of estrogen receptor (ER) status.

Purpose of the Study:

  • To evaluate the therapeutic potential of raloxifene in preclinical models of TNBC.
  • To investigate the underlying mechanisms of raloxifene's action in TNBC.

Main Methods:

  • Administration of varying doses of raloxifene to TNBC mouse models.
  • Monitoring tumor progression, microvessel density, proliferation, apoptosis, migration, invasion, and tumorigenicity.
  • Analysis of epidermal growth factor receptor (EGFR) expression and localization.

Main Results:

  • Raloxifene (0.85 mg/kg) significantly prevented tumor growth and induced regression in TNBC models.
  • Treated tumors exhibited reduced microvascular density (54%), proliferation, and a 7-fold increase in apoptosis.
  • Raloxifene decreased EGFR expression by 27-fold and promoted EGFR translocation to endosomes, inhibiting cell migration, invasion, and tumorigenicity.

Conclusions:

  • Raloxifene demonstrates significant therapeutic value in TNBC mouse models, acting independently of the ER.
  • The mechanism involves downregulating EGFR signaling, suggesting raloxifene as a potential treatment for TNBC progression.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...